Business Wire

flutiform® Receives a Positive Opinion in Europe for the Treatment of Children with Asthma

Del

The Mundipharma network of independent associated companies today announced that the European Decentralised Procedure (DCP) licence variation application for flutiform ® , extending the indication to the treatment of asthmatic children, has closed with a positive opinion. flutiform ® is a combination of fluticasone propionate and formoterol in a single pressurised metered dose inhaler (pMDI), otherwise known as a press and breathe aerosol inhaler. It is now indicated at a dose of two puffs (actuations) 50/5 µg for regular twice-daily, maintenance treatment of asthma in children aged 5 to <12 years when a combination of an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA) is appropriate.1

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181108005407/en/

flutiform ® has been available in Europe for the treatment of asthma in adults and adolescents (≥12 years old) since 2012 and has a tolerability profile supported by extensive clinical evidence and real-world use for six years across Europe and Asia-Pacific regions in this age group.1,4,5,6,7

“We are delighted that the combination aerosol flutiform ® has now been licenced for use in children aged 5 to <12 years in addition to the current indication for adolescents and adults,” said Catriona Cutting, Head of Regulatory Strategy, Mundipharma. “Asthma affects all aspects of children’s and their families’ lives and new treatment options for paediatric asthma are still very much needed.”

Asthma is the most common chronic disease in childhood2 and represents a major health burden.8 Despite the availability of several paediatric treatment options, uncontrolled asthma is still common in children3 and morbidity from the condition is a major health burden for patients, their families and society.8 Poorly controlled asthma in children is associated with time off school, exacerbations and days in hospital.9 Recent studies suggest that poor asthma control may have a greater impact on children than previously thought, including important long-term consequences such as an increased risk of lifestyle-associated diseases and poorer school performance.10

“The paediatric licence indication for flutiform ® is part of Mundipharma’s commitment to provide new treatments to help improve the lives of people affected by asthma,” said Alberto Martinez, President and CEO, Mundipharma International. “The use of this combination is now well established in adults and adolescents, and we are delighted that following this positive opinion we will also be able to offer this combination for the treatment of paediatric patients.”

The licence variation of flutiform ® for use in children was based on efficacy and safety data from two 12-week paediatric studies, which demonstrated that the treatment administered as two puffs (actuations) of 50/5 μg dose b.i.d., was non-inferior on lung function endpoints to the established combination therapy, fluticasone propionate/salmeterol, and had a similar tolerability profile. In addition, during a 24-week extension phase of one of the studies, lung function improvements compared with baseline were sustained.11 The 24-week extension phase also showed that children receiving flutiform ® had growth rates and plasma cortisol levels within the normal ranges. A 28-day knemometry study further found that flutiform ® did not suppress lower leg growth rate compared with baseline.11

flutiform ® is an easy-to-use inhaler, which can be used effectively with or without a spacer (use of a spacer is advised for children who may find coordination of actuation with inspiration difficult).12 The recommended dose of flutiform ® in children is two puffs (actuations) 50/5 µg twice daily (BID).

-Ends-

Notes to editors:

For medical and pharmaceutical trade media only

For further information please visit:

http://www.mundipharma.com/Press/RespiratoryResources/background

http://www.flutiform.com/medical-media

About the Mundipharma network

The Mundipharma global network of privately-owned independent associated companies was founded in 1956 by doctors, and now operates in over 120 countries worldwide. We are focused on developing business partnerships to identify and accelerate meaningful technology across an increasingly diverse portfolio of therapy areas including respiratory, diabetes, oncology, pain, and biosimilars. Consistent with our entrepreneurial heritage, we like to think we see what others don’t by challenging conventional wisdom and asking different and challenging questions. By working in partnership with all our stakeholders, the Mundipharma global network develops medicines that create value for patients, payers and wider healthcare systems.

For more information please visit: www.mundipharma.com .

About flutiform ®

In Europe, flutiform ® is licenced for regular twice-daily, maintenance treatment of asthma in patients aged 5 years and over when use of a combination product (an inhaled corticosteroid [ICS] and a long-acting β2-agonist [LABA]) is appropriate. As of November 2018, it is available in 21 countries across Europe including the UK, Germany, France, Spain and Italy. flutiform ® is available in 50/5μg strength for children aged 5 to <12 years, in 50/5μg and 125/5μg strengths for adults and adolescents and 250/10μg strength for adults only.

About asthma

Asthma is a chronic inflammatory disorder of the airways which leads to recurrent episodes of wheezing, breathlessness, chest tightness and coughing. Patients with poorly managed asthma are at an increased risk of exacerbations, hospitalisation and death. Poorly managed asthma can also have a huge impact on a person’s quality of life and day-to-day activities.13

® FLUTIFORM is a registered trade mark of Jagotec AG and is used under licence.

References:

1 flutiform ® Summary of Product Characteristics

2 Lung Health in Europe. Facts and Figures. European Lung Foundation 2013 http://www.europeanlung.org/assets/files/publications/lung_health_in_europe_facts_and_figures_web.pdf

3 Byrne P, et al. The Poorly Explored Impact of Uncontrolled Asthma. CHEST 2013. 143(2) 511-523

4 Bodzenta-Lukaszyk A, R Buhl, et al. Fluticasone/formoterol combined in a single aerosol inhaler vs budesonide/formoterol for the treatment of asthma: a non-inferiority trial. Eur Respir J 2011a;38:153s

5 Bodzenta-Lukaszyk A, Dymek A et al. Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study. BMC Pulm Med J. 2011;11:28

6 Bodzenta-Lukaszyk A, Pulka et al. Efficacy and safety of fluticasone and formoterol. Respir Med J. 2011;105(5):674-82

7 Backer V, et al. Real-world study to evaluate the safety and effectiveness of fluticasone propionate/formoterol (FP/FORM) in patients with asthma. Abstract FLT9503, European Respiratory Society (ERS) 2017, Milan

8 European Respiratory Society. Childhood asthma. The European Lung White Book. 2013

9 Asher, et al. Global burden of asthma among children. Int J Tuberc Lung Dis 2014. 18(11):1269–1278

10 Pedersen S. Asthma control in children: Is it important and can we measure it? Paediatr Respir Rev 2016; 17:36-8. doi: 10.1016/j.prrv.2015.08.009. Epub 2015 Oct 31. https://www.ncbi.nlm.nih.gov/pubmed/26531216

11 Wolthers O, et al. Short-Term Growth During Treatment with Inhaled Fluticasone Propionate/Formoterol, Fluticasone and Beclomethasone Treatment 2017. J Aerosol Med Pulm Drug Deliv. 2017 Oct;30(5):373-380

12 GINA, Global Strategy for Asthma Management and Prevention 2018

13 Raimundo K, et al. Relationships between asthma control, productivity and health outcomes in a US survey. European Resp J 2016 48: PA4219; DOI: 10.1183/13993003.congress-2016.PA4219

Contact information

Tiffany Fretwell
Communications Lead, Mundipharma International Ltd
E-mail: Tiffany.Fretwell@mundipharma.com
Tel: +44 (0) 7773 199 422
or
Nicola Lilley
Account Director, Havas SO
E-mail: Nicola.Lilley@HavasSO.com
Tel: +44 (0) 7983 128 712

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

OnMiners Changing the Game in Cryptocurrency Mining18.3.2019 20:25:00 CETPressemelding

OnMiners S.A (www.onminers.com) has recently earned the distinction becoming the first company ever to introduce an extraordinary range of endothermic cryptocurrency mining rigs. A team of investors working towards making crypto mining simple and profitable, OnMiners has introduced three highly efficient mining rigs utilizing the latest endothermic chip technology. Each of these products offers biggest hash-rates available in the market while minimizing power consumption and heat/noise generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190318005779/en/ On2U (Photo: Business Wire) The three OnMiners mining rigs named On2U, On4U, and OnTower can mine Bitcoin, Litecoin, Ethereum, Monero, Dash, and Zcash. Users can start mining their preferred coins immediately because all the units come pre-configured and just need to be plugged in. The most noteworthy feature of these mining rigs is their endothermic nature. Unlike any

AGCO Announces Strategic Partnership with Solinftec18.3.2019 19:31:00 CETPressemelding

AGCO Corporation (NYSE:AGCO), a world-leading manufacturer and distributor of agricultural equipment solutions, announces a commercial and technological partnership with Solinftec, a world-leading developer and distributor of digital agriculture solutions. The partnership will give AGCO customers direct access to Solinftec´s portfolio of solutions including on-board computers, weather stations, soil sensors, telemetry networks, proprietary algorithms and the real-time generation of actionable insights generating operational efficiency and agronomic efficacy. The new solutions will launch in Brazil beginning in early 2019 for growers of sugarcane, soybean, corn and cotton and will launch in the United States for the 2020 crop cycle for corn and soybean growers. Solinftec’s offerings will complement the fleet and farm solutions already available through AGCO’s Fuse® smart farming portfolio. For 11 years, Solinftec has brought solutions to its clients that capture and process data real-ti

Epiphany Partners with Konsentus to Advance Open Banking Era18.3.2019 17:00:00 CETPressemelding

Fintech software and solution innovator, Epiphany SRI, today announced a partnership with regtech company, Konsentus. As a result of this partnership, financial organizations will be able to build open digital banking platforms that comply with PSD2 regulations. The deadline for organizations to comply with PSD2 regulations was 14 March 2019. The regulations require legacy banking and financial service providers, that hold online accessible client accounts, to provide Application Programming Interface (API) so that new operators, Third Party Providers (TPP), can develop new services including order placement, payment or account information. The Epiphany Open Digital Banking Platform helps banking and financial organizations remain relevant, and satisfy their customers’ current and future banking needs, by providing access to an ecosystem of advanced financial services. Konsentus is the only live Software as a Service (SaaS) based API solution available to check TPP Identity and Regulat

HubHead Certifies NRX AssetHub 7.0 for Use with SAP NetWeaver®18.3.2019 16:15:00 CETPressemelding

HubHead announces that NRX AssetHub 7.0 has been certified by SAP NetWeaver® 7.3. This SAP certification states that NRX AssetHub 7.0 integrates with SAP NetWeaver and that it complies with all the technical requirements for the SAP certification procedures. This certification means that NRX AssetHub 7.0 can efficiently integrate with SAP® solution environments. NRX AssetHub 7.0 can easily be implemented into SAP® infrastructure, quickly and at a low cost. Dennis Wu, the senior vice president of engineering at HubHead says, “We are excited to receive the SAP NetWeaver certification for the next generation of the NRX AssetHub solution.” HubHead Corp is Sponsoring SAP-Centric EAM: The HubHead team is at SAP-Centric EAM in San Antonio as a Silver Sponsor. SAP-Centric EAM is North America’s only asset management conference powering SAP users. You are encouraged to visit the HubHead team and take advantage of the coffee barista station. A HubHead customer in the oil and gas industry will be

TRIPLE-1, Inc. Signed a Distributorship Contract with Fujitsu Electronics Inc.18.3.2019 15:00:00 CETPressemelding

TRIPLE-1, Inc. (Representative Director: Takuya Yamaguchi) and Fujitsu Electronics Inc. (Representative Director: Junji Ogihara) have entered into a distributorship contract for a mining ASIC (application specific IC) “KAMIKAZE” that uses the world's most advanced 7nm process technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190318005034/en/ TRIPLE-1 / Fujitsu --- Background: In the development market for mining ICs, which requires huge computing power and high power efficiency, the introduction of advanced process technology has been attempted positively and just like the development market for ICs for smartphones, which is one of the world's leading manufacture industries, the driving force for development came from the process miniaturization in the advanced semiconductor industry. As of 2019, there is a mover away from the mainstream 16nm process which had been the oligopoly of traditional Chinese region manufac

Survey Says: Project Leaders Need More PMTQ18.3.2019 14:00:00 CETPressemelding

Project Management Institute (PMI) today released its Pulse of the Profession® report which reveals that organizations wasted almost 12 percent of their investment in project spend last year due to poor performance—a number that’s barely budged over the past five years. As a solution, PMI is calling on project leaders worldwide to evaluate and bolster their Project Management Technology Quotient or PMTQ. PMI developed the tenets of PMTQ by drawing on insights from innovator companies that put a high priority on digital skills acquisition and knowledge coupled with a commitment to a strong project management culture. PMTQ adds a layer of project management to the concept of technology quotient (TQ), which is defined as a person’s ability to adapt, manage and integrate content advances in technology for a project or organization. "In jobs of the future, project teams will be more and more reliant on technology as either an enabler or sometimes as a team member," said Murat Bicak, Senior